Macroaxis: Personalized Investing
Simple Personalized Investing

GILD AMGN BIIB CELG Rentals Market Drivers Office Supplies Currently Hot 
Benchmark SP 500  1,650   0.91  Index Moved Down -0.06% ...


Processing
Collecting data for ILMN

Illumina quote and profile

 
 Companies |  Insiders  | Dashboard  
     
70.31
  
STOCK
(0.77)  Macroaxis: -1.08 Down   1.08%  
Year To Date
37.7773.08
Last 1 Month(s)
62.5473.08
Trading Day 
69.8170.78
May 24 2013 

Diversification Suggestion

Use Illumina to protect against small markets fluctuations. The stock experiences somewhat bearish sentiment, but market may correct it shortly
Analyze Illumina Inc Trend or Check current 30 days Illumina correlation with market (S&P 500)
1 Month Beta 1.92  
Highest Price:  
Lowest Price:  
73.08  
62.54  
May 20 2013 
April 25 2013 
As market goes up, the company is expected to significantly outperform it. However, if the market returns are negative, Illumina will likely underperform.
Illumina Inc Large BetaIllumina Inc Beta Legend
ILMN United States Nasdaq
Illumina Inc
Healthcare
Biotechnology
Benchmark S&P 500
http://www.illumina.com
Contact Number: 858. 202. 4500
Currency: USD - US Dollar
Traded on NASDAQ
    
Current Valuation7.86 B
Shares Outstanding124.38 M
Number of Shares Shorted28.58 M
Revenue1.21 B
 United States Nasdaq   0.97 % Macroaxis: 0.97 Moved Up  
 
 United States Russel   0.00 % No Change  
 United States SP 500   0.06 % Macroaxis: 0.06 Moved Down  
 
 United States NYSE   0.26 % Macroaxis: 0.26 Moved Down  
 
 thisRed ILMN ILMN agains markets  1.08 % Macroaxis: change 1.08 Moved Down  
 
Compare to Competition Get Alpha   Get Advice

Illumina Leadership

Jay Flatley CEO and President and Director
Jason Flatley CEO and President and Director
William Rastetter Chairman of the Board, Ph.D
Mostafa Ronaghi CTO, Senior Vice President, Ph.D

Illumina Price and Market Media

The median price of Illumina for the period between Wed, Apr 24, 2013 and Fri, May 24, 2013 is 67.16 with a coefficient of variation of 5.12. The daily time series for the period is distributed with a sample standard deviation of 3.46, arithmetic mean of 67.56, and mean deviation of 3.03. The Stock received substential amount of media coverage during this period.
Illumina         SP 500
Price Growth (%)
 
1
ILLUMINA INC. Verinata Health Publishes Clinical Laboratory ...04/26/2013Macroaxis: News
2
ILLUMINA INC. Illumina to Webcast Live Presentation at Upcom...05/02/2013Macroaxis: News
3
Best 5 and Worst 5 Biotech Stocks Sequenom Theravance MannKi...05/14/2013Macroaxis: News
4
ILLUMINA INC. Illumina Launches BaseSpace Apps05/17/2013Macroaxis: News
5
Illumina Inc. Presents at UBS Global Healthcare Conference M...05/21/2013Macroaxis: Seeking Alpha News

Illumina Summary

Illumina Inc [ILMN] is traded on NASDAQ in USA. It is located in San Diego, CA and employs 2,400 people. The company currently falls under 'Mid-Cap' category with current market capitalization of 8.7 B. Illumina Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 124.38 M outstanding shares of which 28.58 M shares are currently shorted by private and institutional investors with about 30.3 trading days to cover.
Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the AsiaPacific, the Middle East, and South Africa. more
Past Market
Over 30
Days
18
Out Of
100
 
Chance of
Less
Than
11 %
 
Follow Illumina with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add Illumina to your reader
 

Illumina Research Report

Illumina vs. Gilead

Correlation analysis and fundamentals comparison between Illumina Inc and Gilead Sciences

Illumina Executives

Marc Stapley CFO and Sr. VP

Illumina Directors

Paul Grint Independent Director
Rebecca Chambers Senior Director - Investor Relations
Karin Eastham Independent Director, MBA
Gerald Moller Independent Director, Ph.D
Robert Epstein Director

Illumina Management

Christian Cabou Sr. VP, General Counsel and Secretary
Christian Henry Sr. VP and General Manager of Genomic Solutions
Paul Bianchi Sr. VP of HR

Illumina Fundamentals

EBITDA vs Current Ratio
Return On Equity vs Retained Earnings
EBITDA vs Shares Outstanding
Profit Margin vs Retained Earnings

Illumina vs Competition

Illumina vs. Gilead Sciences Inc
Illumina vs. Amgen Inc
Illumina vs. Biogen Idec Inc
Illumina vs. Celgene Corporation
Illumina vs. Regeneron Pharmaceuticals Inc
Illumina vs. Alexion Pharmaceuticals Inc
Illumina vs. Vertex Pharmaceuticals Incorporated
Illumina vs. BioMarin Pharmaceutical Inc
Illumina vs. Onyx Pharmaceuticals Inc

Illumina May 24 2013 Opportunity Range

Downside Deviation1.38
Information Ratio0.2238
Maximum Drawdown6.8
Value At Risk(1.69)
Potential Upside3.37

 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium